CTFN's #ICYMI weekend edition: #Merger and deal activity are expected to be robust in 2021, and regulator scrutiny is expected to be rigorous.

(thread) #antitrust #investming #stocks

In the meantime, key changes will occur under the new #Biden administration at the U.S. Federal Trade Commission that is anticipated to weigh heavily on big pharma deals, @dalter28 wrote

#FTC #antitrust #MnA

Further for one big pharma deal, Surani Fernando wrote that while @AstraZeneca's $39 billion bid for @AlexionPharma has drawn a number of critics, a strategic build-out of immunology may prove an important rationale for the deal

#mergers #healthcare $ALXN $AZN

On @Google's acquisition of @Fitbit: the @acccgovau rejected #Google's offer of behavioral remedies this week, though a former ACCC official walked CTFN through how the parties might handle the review

#HeyGoogle #ACCC

The Russian regulatory process for Nova Resources' proposed buyout of Kaz Minerals is unlikely to exceed the standard timeline, CTFN's @CamerinoValeria reported

#shareholders #mergers #mining